Literature DB >> 16078230

Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.

Christophe F Chantrain1, Priscilla Jijon, Thomas De Raedt, Christiane Vermylen, Hélène A Poirel, Eric Legius, Bénédicte Brichard.   

Abstract

A 4-year-old girl with Noonan syndrome (NS) and constitutive PTPN11 mutation presented with stage 4 neuroblastoma and was treated by intensive chemotherapy. During the treatment, cytogenetic analysis revealed the development of a hyperdiploid clone with duplication of the germline PTPN11 mutation in a morphologically normal bone marrow. A few months later, the patient developed acute myelomonoblastic leukemia with an additional clonal deletion of 7q. Although, we cannot conclude whether there is an association between NS and neuroblastoma, this case suggests that duplication of germline PTPN11 mutations, potentially induced by chemotherapy, contributes to leukemogenesis in patients with NS. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16078230     DOI: 10.1002/pbc.20527

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

Review 1.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 2.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

3.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

4.  Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.

Authors:  Xia Liu; Hong Zheng; Xiaobo Li; Siying Wang; Howard J Meyerson; Wentian Yang; Benjamin G Neel; Cheng-Kui Qu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

Review 5.  Genetic susceptibility to neuroblastoma.

Authors:  Vanessa P Tolbert; Grace E Coggins; John M Maris
Journal:  Curr Opin Genet Dev       Date:  2017-04-28       Impact factor: 5.578

6.  Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.

Authors:  Marjolijn C J Jongmans; Ineke van der Burgt; Peter M Hoogerbrugge; Kees Noordam; Helger G Yntema; Willy M Nillesen; Roland P Kuiper; Marjolijn J L Ligtenberg; Ad Geurts van Kessel; J Han J M van Krieken; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

7.  Noonan syndrome - a new survey.

Authors:  Alireza Tafazoli; Peyman Eshraghi; Zahra Kamel Koleti; Mohammadreza Abbaszadegan
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

Review 8.  Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.

Authors:  Stefano Stagi; Vittorio Ferrari; Marta Ferrari; Manuela Priolo; Marco Tartaglia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.